Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
Eur Urol Oncol · 2026-Apr · PMID 39542826
Overall Survival
Fig. 1 – Cumulative incidence and survival plots by prostate subtyping classifier (PSC) subtype for six prostate cancer endpoints. Here, outcomes after treatment by binary PSC subtype categorization (basal subtype [basal immune or basal neuroendocrine] vs luminal subtype [luminal differentiated or luminal proliferating]) are shown for (A) biochemical failure, (B) distant metastases (DMs), (C) metastasis-free survival (MFS), (D) prostate cancer–specific mortality (PCSM), (E) other-cause mortality (OCM), and (F) overall survival (OS). The plots represent the cumulative incidence for endpoints where death serves as a competing risk (BF, DM, PCSM, and OCM) and Kaplan-Meier estimated survival for other endpoints (MFS and OS). BF = biochemical failure; CI = confidence interval; HR = hazard ratio; sHR = subdistributional hazard ratio.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:15:02+00:00 |